spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.

Chiltern

Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

London, U.K., Wilmington, N.C. and Tokyo, Japan; May 31, 2017 (Business Wire)Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections. 

“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”

IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger, will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.

To learn more about Chiltern’s global clinical development services, visit Chiltern.com.

About Chiltern

Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.
phone UK:+44(0)1753 512 000; US:+1 (423) 968 9533
email info@chiltern.com
web www.chiltern.com
email UK: 171 Bath Road, Slough, Berkshire, SL1 4AA. US: 3147 S. 17th Street, Suite 300 Wilmington, NC 28412.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am ET on June 20.
More info >>


White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

Industry Events

3rd PDA Europe Annual Meeting

26-27 June 2018, Berlin Marriott Hotel

The ongoing theme of the European Annual Meeting is Global Healthcare of the Present & the Future, as it intends to continue spanning a bridge between current demands within the global healthcare industry, the amounting advanced technological and analytical opportunities and the promising prospects personalized medicine and medicinal products bring.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement